Moreover, pharmacodynamic studies in vivo showed that compound 6 could significantly inhibit pulmonary vascular remodeling, improve RVH, and reduce the mPAP in hypoxia-induced PAH rats via disrupting the Hsp110-STAT3 interaction. Here, STAT3 is linked to pulmonary arterial hypertension.